Authors
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Hailey Frye discusses improvement of pain management for nephrolithiasis“The benefit of being here at the University of Minnesota is that we have a bunch of different types of settings to be able to trial this," says Hailey Frye.
Latest:
Chad Ritenour, MD, on efforts to promote physician well-being at Emory Urology“One of the ways we make the most difference for our patients is we take care of the people who are taking care of them,” says Chad Ritenour, MD.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Workplace violence in health care remains rampant as preventive efforts continueEven before the pandemic, violence against health care workers was escalating.
Latest:
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Latest:
Bridget Koontz, MD, on PSMA-PET’s impact on treatment planning“For us, being able to know where the cancer is allows us to target it, and I think that lets us be much more effective with our treatment,” says Bridget F. Koontz, MD, FASTRO.
Latest:
Is video-based research feasible for pediatric urology visits?"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.
Latest:
FDA approves niraparib/abiraterone tablet for BRCA-positive mCRPCThe approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.
Latest:
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA ResponseA panelist discusses how patients with high-risk localized prostate cancer receiving treatment intensification should complete an 18- to 24-month course of systemic therapy with radiation for optimal cure rates, rather than stopping early due to prostate-specific antigen (PSA) response alone.
Latest:
Better evidence for efficacy of postmenopausal incontinence treatments neededUrinary symptoms were not significantly improved from local estrogen use in most studies, though an improvement in vaginal symptoms was observed.
Latest:
Study shows proof of concept for sustained release with TAR-200“It's the sustained release and constant exposure to the gemcitabine that's most likely responsible for the high efficacy rates of that we're seeing with the TAR-200 system,” says Siamak Daneshmand, MD.
Latest:
Administering onabotA: Improving patient comfort and easing anxietyAn expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.
Latest:
Ziho Lee, MD, previews 2025 Northwestern GU robotic reconstruction courseThe course addresses "unicorn cases" in the upper tract—unique and challenging situations lacking established guidelines or literature.
Latest:
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomyThe trial has enrolled 201 patients with localized prostate cancer to date.
Latest:
Fluoroscopic Imaging and Other Developments in UrologyThe rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.
Latest:
Urologic research and COVID-19: Unmasking the silver liningIn this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Latest:
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI“Now, at 1 year, the 1-hour pad test has been done again, as it's part of the protocol, and she suffered 4 g of incontinence on this test, opposed to 125 g at the beginning,” says Emmanuel Chartier-Kastler, MD, PhD.
Latest:
What factors affect patient reviews of urologists?"What we found is that it's very difficult to raise your review on these websites, but fairly easy to drop your review," says Jake Miller, MD.
Latest:
Treatment and Co-Management of mCRPC Patients with Aggressive DiseaseThis video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.
Latest:
Forward Looking NMIBC Treatment Advancements and Needs in 2024In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
Latest:
ARV-766 shows promising efficacy and tolerability in mCRPCResults presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.
Latest:
Money Matters: Expert on why annuities are the “Swiss Army knife” of personal financeSocial Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.
Latest:
Vaginal prolapse repair and sling surgery significantly reduce UUI"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Latest:
Pearls & Perspectives: Urology's role in GLP-1 RA treatments, with Hossein Sadeghi-Nejad, MD, and Nathalie Eid, BAThis episodes explores the evolving role of GLP-1 medications in testosterone management and their impact on male sexual health and fertility.
Latest:
Geoffrey Sklar, MD, on integrating AI in a way that augments urologic care“I think this is the future, and if we don't go down that path and we don't explore, we're not going to make it better for us and for the patients,” says Geoffrey N. Sklar, MD, FACS.
Latest:
Biomarkers in urology: Policy and legislative advances"The AACU has been discussing the evolution of state policy to ensure that biomarker testing, including PSA screening, is covered by payers," writes Ron Lanton, Esq.
